Summary:
A Phase 2 study evaluating a new oral treatment for patients with type 2 Diabetes Mellitus, dosing will occur from 12 to 26 weeks followed by a 6 month follow up period.
Criteria:- Have been diagnosed with Type 2 Diabetes Mellitus within the last 7 years
- Hemoglobin a1c lab test between 7 - 10.5%
- BMI >25 but less than 40kg/m2
- Must not be a heavy smoker
- Not currently using insulin
Qualified Participants May Receive:
Compensation for time and travel at each study visit, up to $2,450 total